Published in Am J Pathol on May 01, 2000
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53
Histopathological identification of colon cancer with microsatellite instability. Am J Pathol (2001) 2.90
Recent progress in pancreatic cancer. CA Cancer J Clin (2013) 2.88
Pancreatic carcinogenesis. Pancreatology (2008) 2.60
Genetic progression in the pancreatic ducts. Am J Pathol (2000) 2.58
Risk of pancreatic cancer in families with Lynch syndrome. JAMA (2009) 2.32
Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol (2002) 1.96
Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol (2002) 1.72
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol (2003) 1.68
Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol (2011) 1.65
Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. Clin Cancer Res (2009) 1.65
Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome Res (2011) 1.47
Molecular signatures of pancreatic cancer. Arch Pathol Lab Med (2011) 1.46
Genetic alterations in pancreatic carcinoma. Mol Cancer (2003) 1.43
Hereditary pancreatic cancer. Gastroenterology (2010) 1.31
Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res (2009) 1.28
Genetic abnormalities in pancreatic cancer. Mol Cancer (2003) 1.07
Epigenetics and epigenetic alterations in pancreatic cancer. Int J Clin Exp Pathol (2008) 1.05
Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J Mol Diagn (2008) 1.04
Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry. Fam Cancer (2013) 1.03
Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.01
Current knowledge on pancreatic cancer. Front Oncol (2012) 1.01
The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. J Pathol (2010) 1.00
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther (2015) 0.97
Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol (2014) 0.95
Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome. Am J Surg Pathol (2009) 0.94
Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs). Langenbecks Arch Surg (2008) 0.90
Emerging molecular biology of pancreatic cancer. Gastrointest Cancer Res (2008) 0.87
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology (2015) 0.86
Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects. Am J Pathol (2001) 0.86
Correlation between patterns of DNA mismatch repair hmlh1 and hmsh2 protein expression and progression of dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Virchows Arch (2004) 0.85
Pathology and molecular genetics of pancreatic neoplasms. Cancer J (2012) 0.85
Pathological and molecular evaluation of pancreatic neoplasms. Semin Oncol (2014) 0.83
Genetics and pathology of pancreatic cancer. HPB (Oxford) (2006) 0.82
Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma. PLoS One (2012) 0.81
Current approaches to novel therapeutics in pancreatic cancer. Invest New Drugs (2003) 0.81
A histomorphologic comparison of familial and sporadic pancreatic cancers. Pancreatology (2015) 0.81
Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes. Sci Rep (2017) 0.80
Early detection of pancreatic cancer. Chin J Cancer Res (2015) 0.80
Adenocarcinoma of the pancreas. Semin Diagn Pathol (2014) 0.80
EBV-associated lymphoepithelioma-like carcinoma of the pancreas: Case report with targeted sequencing analysis. Pancreatology (2015) 0.79
Genomic landscapes of pancreatic neoplasia. J Pathol Transl Med (2015) 0.78
[Pancreatic ductal adenocarcinoma and its precursors]. Pathologe (2005) 0.78
Patterns of pancreatic resection differ between patients with familial and sporadic pancreatic cancer. J Gastrointest Surg (2011) 0.78
Personalized therapy for pancreatic cancer: Myth or reality in 2010? J Gastrointest Oncol (2010) 0.77
The role of tobacco-derived carcinogens in pancreas cancer. ISRN Oncol (2011) 0.77
Association between the hMSH2 IVS12-6 T>C polymorphism and cancer risk: A meta-analysis. Exp Ther Med (2011) 0.75
Genetic factors affecting patient responses to pancreatic cancer treatment. Ann Gastroenterol (2016) 0.75
Hepatoid carcinoma of the pancreas with lymphoid stroma: first description of the clinical, morphological, immunohistochemical, and molecular characteristics of an unusual pancreatic carcinoma. Virchows Arch (2015) 0.75
Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst (1959) 94.48
ras genes. Annu Rev Biochem (1987) 22.59
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell (1988) 10.29
Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun (1985) 6.57
A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst (1997) 5.68
Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci U S A (1993) 5.47
Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res (1993) 4.93
Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res (2000) 3.74
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res (1996) 3.60
K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol (1993) 3.56
Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res (1995) 3.33
KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res (1988) 3.31
Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res (1996) 2.89
Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol (1999) 2.59
Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res (1998) 2.23
Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. JAMA (1999) 2.14
Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. Proc Natl Acad Sci U S A (1998) 2.14
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res (1998) 1.97
Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors. Am J Surg Pathol (1999) 1.85
Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod Pathol (1990) 1.83
High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer (1989) 1.79
BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol (2000) 1.72
Morphological patterns of primary nonendocrine human pancreas carcinoma. Cancer Res (1975) 1.55
Pathology of hereditary non-polyposis colorectal cancer. Anticancer Res (1994) 1.49
Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol (1998) 1.42
Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch Syndrome). Int J Cancer (1996) 1.38
Detection and characterization of Epstein-Barr virus in clinical specimens. Am J Pathol (1994) 1.34
Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer (1985) 1.34
Systemic cancer and the FAMMM syndrome. Br J Cancer (1990) 1.12
Pathology of incipient pancreatic cancer. Ann Oncol (1999) 1.10
Molecular characteristics of poorly differentiated adenocarcinoma and signet-ring-cell carcinoma of colorectum. Int J Cancer (1999) 1.09
Unbalanced germ-line expression of hMLH1 and hMSH2 alleles in hereditary nonpolyposis colorectal cancer. Cancer Res (1999) 1.06
Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin N Am (1998) 1.05
Epstein-Barr-encoded RNA in situ hybridization: diagnostic applications. Hum Pathol (1994) 1.02
A rapid and simple procedure for the routine detection of ras point mutations in formalin-fixed, paraffin-embedded tissues. Diagn Mol Pathol (1992) 0.99
Detection of mismatched bases in double stranded DNA by gel electrophoresis. Electrophoresis (1995) 0.97
Epstein-Barr virus-associated gastric carcinoma in Mexico: analysis of 135 consecutive gastrectomies in two hospitals. Mod Pathol (1999) 0.95
Detection of mutations in multi-exon genes: comparison of conformation sensitive gel electrophoresis and sequencing strategies with respect to cost and time for finding mutations. Hum Mutat (1997) 0.90
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 11.13
Gene expression profiles in normal and cancer cells. Science (1997) 9.65
Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg (1997) 8.86
Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med (2000) 8.68
Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg (2001) 8.34
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Brief physician advice for problem alcohol drinkers. A randomized controlled trial in community-based primary care practices. JAMA (1997) 8.05
Socio-economic differences in health, nutrition, and population within developing countries: an overview. Niger J Clin Pract (2007) 6.38
Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol (2001) 6.30
Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med (2000) 6.27
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med (1993) 6.13
Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell (1998) 5.88
One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg (1993) 5.87
Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg (1995) 5.66
Allelotype of colorectal carcinomas. Science (1989) 5.54
Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg (1996) 5.42
Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 5.10
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Progression model for pancreatic cancer. Clin Cancer Res (2000) 4.60
Characterization of degP, a gene required for proteolysis in the cell envelope and essential for growth of Escherichia coli at high temperature. J Bacteriol (1989) 4.56
Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med (1987) 4.55
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg (1998) 4.19
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (2001) 4.19
Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet (1996) 4.09
Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther (2012) 4.05
Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg (1997) 3.90
Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg (1991) 3.88
Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. Am J Clin Nutr (1997) 3.75
Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res (2000) 3.74
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med (2000) 3.70
Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet (1994) 3.69
Scrambled exons. Cell (1991) 3.65
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res (1996) 3.60
Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell (1991) 3.59
K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol (1993) 3.56
Highly constrained backprojection for time-resolved MRI. Magn Reson Med (2006) 3.53
Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant (1996) 3.51
Drosophila Mad binds to DNA and directly mediates activation of vestigial by Decapentaplegic. Nature (1997) 3.34
Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res (1995) 3.33
Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 3.31
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol (2001) 3.27
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
Distal pancreatectomy: indications and outcomes in 235 patients. Ann Surg (1999) 3.09
Characterization of leucocin A-UAL 187 and cloning of the bacteriocin gene from Leuconostoc gelidum. J Bacteriol (1991) 3.02
The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res (2001) 3.02
Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg (2000) 2.94
Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res (1998) 2.89
p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res (1997) 2.88
Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med (1989) 2.81
p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res (1994) 2.80
Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg (2001) 2.80
The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev (1998) 2.72
Origin of the expansion mutation in myotonic dystrophy. Nat Genet (1993) 2.70
Oxonium ions from aqua regia: isolation by hydrogen bonding to crown ethers. Inorg Chem (2001) 2.68
An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol (1994) 2.67
Evaluation of rooms with negative pressure ventilation used for respiratory isolation in seven midwestern hospitals. Infect Control Hosp Epidemiol (1993) 2.65